Press Releases

2017

SAN DIEGO, CA June 19, 2017 – Aragen Bioscience, Inc, a leading pre-clinical contract research organization specializing in the discovery and preclinical development of high-value biotech and pharmaceutical products, announced today at the BIO International Convention the introduction of RapTr™ services. RapTr™ Cell Line Development Services combine the proven CHO-DG44 host cell line and vector combination with an innovative clone selection process. The results are a highly flexible and customizable platform delivering high titers in a rapid timeframe from early stage Discovery through to the Clinic. RapTr also incorporates state-of-the-art analytical methods to characterize and evaluate product quality at all stages.  As RapTr is based on CHO-DG44, it is regulatory-friendly and royalty-free.

“Building on our decades of experience in cell line development and recent investments in expanding our biologics team and facilities, we’re excited to announce RapTr™. We believe that our suite protein expression and analytical services will give our clients tremendous flexibility in developing cell lines and generating high quality proteins using a single scalable platform regardless of their stage of development.” said Oren Beske, Ph.D., President of Aragen Bioscience.

About Aragen Bioscience, Inc.

Aragen Bioscience, Inc., a wholly-owned subsidiary of GVK Bio, is a leading contract research organization based in the San Francisco Bay Area. Aragen Bioscience offers a diverse set of in vitro and in vivo services for the discovery, characterization, activity assessment and early development of biologic and diagnostic products. For additional information, please visit www.aragenbio.com.

2016

July 11, 2016
MORGAN HILL, California – July 11, 2016: Aragen Bioscience, Inc. (Aragen), leading pre-clinical contract research organization specializing in the discovery and early development of high-value biologics and diagnostic products has appointed Oren Beske, Ph.D. as the President of Aragen Bioscience.

January 26, 2016
MORGAN HILL, California – January 28, 2016: Aragen Bioscience, Inc. (Aragen), leading contract research organization specializing in the study and early development of biologic and diagnostic products, has initiated construction on a new, state of the art research facility.

2015

September 8, 2015
Aragen Bioscience Announces Licensing Agreement for Protein Production Technology from ProteoNic Biotechnology


2014

January 2, 2014
GVK BIO and Aragen Bioscience Sign Definitive Agreement to Acquire Aragen Bioscience, Inc.


2013

May 2, 2013
Aragen Bioscience and Innovent Biologics Announce Collaboration for Biotherapeutic Product Development

September 12, 2013
Bullet Bio Provides Update On Recent Financing And Results From Proof-Of-Concept Study For Lead Product Candidate


2012

August 2, 2012
Aragen Bioscience, Inc. successfully completes antibody humanization project


2011

October 26, 2011
XOMA and Aragen Bioscience Announce Antibody Humanization Services AgreementXOMA and Aragen Bioscience Announce Antibody Humanization Services Agreement

June 1, 2011
Aragen Bioscience Announces Cooperative Research and Development Agreement with the U.S. Army

April 5, 2011
Aragen Bioscience Awarded Three PreClinical Development NIAID Subcontracts